A Phase 1, OPEN-Label, Non-randomized, Pharmacokinetic Study of TAS-102 in Chinese Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
Price : $35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 02 Aug 2017 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 05 Feb 2017 Planned End Date changed from 1 Aug 2016 to 1 Jun 2017.